Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Cardiovascular Imaging
When measuring LV volumes on Echo using ultrasound enhancing agents, are you using different volume cut offs?
If so, is there a good reference paper?
Related Questions
What are some TTE findings that suggest worsening function of a bioprosthetic AVR that would require further surveillance or diagnostic imaging?
When do you favor using cardiac CT compared to TEE for outpatient surveillance in the immediate post-Watchman period?
How do you distinguish between senile/hypertensive sigmoid septal hypertrophy versus sigmoid septal hypertrophy seen in hypertrophic cardiomyopathy?
Should there be age cut-off considerations when ordering TTEs with bubble routinely as part of stroke work-up?
What is your preferred imaging modality for the evaluation of coronary microvascular dysfunction/INOCA and when would you favor it over coronary angiogram with provocative testing?
What is your approach to determining the safety, appropriateness, and timing of SPECT or PET MPI in patients admitted with NSTEMI and who remain chest pain-free and hemodynamically stable?
Is there any utility in reporting LV strain on echocardiogram for patients with depressed LVEF?
For asymptomatic, incidentally found Lambl's excrescence, should long-term surveillance imaging be considered and if so, how often should repeat imaging be ordered?
When would you consider using cardiac MRI over nuclear imaging for functional assessment of ischemic heart disease, since it is class IIa indication in the US but otherwise class I in Europe?
What is the role of MRI in assessing the risk of embolism in patients with persistent left ventricular thrombus following myocardial infarction?